Smoking and inflammation in laryngeal squamous cell carcinoma

Jelena Sotirović1, Aleksandar Perić1, Danilo Vojvodić1, Nenad Baletić1, Milanko Milojević1, Ljubomir Pavićević1

1Military Medical Academy, Department of Otorhinolaryngology, Belgrade, Serbia; 2Military Medical Academy, Institute for Medical Research, Belgrade, Serbia

SUMMARY
Introduction/Objective Epidemiological studies have established cigarette smoking as one of the most significant risk factors in pathogenesis of laryngeal squamous cell carcinoma (LSCC). One of the possible underlying mechanism is chronic inflammation, but published data regarding the effect of tobacco on systemic immune response is inconsistent.

The goal of this study was to evaluate concentrations of serum proinflammatory cytokines [interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α] in patients with LSCC and in healthy subjects according to cigarette smoking.

Methods Fifty-nine LSCC patients and 44 healthy controls were enrolled in the study. Samples of peripheral blood and details of tobacco use were gathered from the examinees. Flow cytometry was performed to analyze serum concentrations of IL-6, IL-1β, and TNF-α. The results were compared according to active smoking status.

Results Statistical analysis revealed no significant difference between smoking LSCC patients and smoking healthy subjects. Additionally, investigated cytokines were not significantly different in healthy subjects according to smoking status. In non-smoking participants with LSCC, concentrations of serum IL-1β and TNF-α were higher (p < 0.05) in comparison with smoking LSCC patients.

Conclusion Findings of our study may indicate that smoking leads to the suppression of proinflammatory response in LSCC patients, whilst proinflammatory response is unaffected by cigarettes in healthy subjects.

Keywords: smoking; IL-6; IL-1β; TNF-α; laryngeal squamous cell carcinoma

INTRODUCTION
Carcinogenesis is a multifactorial and multistage process in which gene–environment interactions play crucial role. Smoking is well-established as a significant risk factor in laryngeal squamous cell carcinoma (LSCC). One of the most accepted hypotheses in carcinogenesis is chronic inflammation. Inflammation and immune modulation induced by tobacco and asbestos are broadly associated with lung cancer, alcohol consumption, and inflammation of the pancreas with pancreatic cancer, hepatitis B infection with liver cancer, inflammatory bowel disease (Crohn's disease and ulcerative colitis) with colorectal cancer. Despite the established evidence of the causal relationships between smoking and elevated cancer risk, the underlying mechanism has not been completely understood. The fact that not all smokers develop cancer suggests individual susceptibility for developing malignant disease. Recently published literature reports genetic and epigenetic changes induced by tobacco carcinogens in head and neck carcinoma [1]. Additionally, in previously published literature, nicotine was found to exert both pro-inflammatory and anti-inflammatory effects [2]. Virchow noticed over a 100 years ago that histologic appearance of tumor tissue resembles the histologic change seen in unhealed wound [3]. Conversely, Coley [4] reported regression of the malignant tumor following bacterial infection. Today, inducing strong infection and inflammation by Mycobacterium bovis, bacillus Calmette–Guerin (BCG) in bladder carcinoma is standard antitumor therapy.

Association between cancer and inflammation is reflected by the presence of numerous proinflammatory cytokines in cancer. It is believed that mediators released by host inflammatory cells or cancer cells are involved in tumor initiation, promotion, and progression. Given that inflammation can have both pro-tumorigenic and anti-tumorigenic effect, it seems that the role of inflammation in tumorigenesis depends on the interaction between tumor cells, immune cells, and inflammatory cells. Since deregulated inflammation is a significant factor in carcinogenesis of numerous malignant tumors, identifying the mechanisms by which inflammation is deregulated in cancer may improve antitumor therapeutic strategies.

The goal of this research was to reveal the relations between smoking and concentrations of serum proinflammatory cytokines TNF-α, IL-6, and IL-1β in patients with LSCC and in healthy subjects.
METHODS

The research was performed as a cross-sectional study of 59 patients with LSCC (40 smokers, 19 non-smokers). All the patients were diagnosed at a tertiary referral center. The diagnosis of LSCC was confirmed clinically, histopathologically, and radiologically. The control group included 44 subjects (14 smokers, 30 non-smokers), healthy volunteers with normal fiberoptic laryngeal findings.

Informed consent was collected from both patients and controls following the hospital’s ethics committee-approved protocol. Exclusion criteria were as follows: any other previous or present malignant or autoimmune disease, history of allergies, co-existing infectious disease, systemic corticosteroid or any immunomodulating therapy.

We defined active smoking as consuming more than 20 cigarettes per day during the period of the last five years.

Samples of peripheral venous blood (5 ml) were taken from all LSCC patients and healthy individuals included in the study, then allowed to clot for 30 minutes. Serum was separated, aliquoted and stored at -80°C until cytokine detection. Flow cytometric kit (FlowCytomix™ Multiple Analyte Detection System, Human FlowCytomix™ Inflammation Panel, eBioscience, Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to measure the serum levels of TNF-α, IL-6, and IL-1β on the flow cytofluorimeter (Beckman Coulter XL-MCL, USA), which was connected with BMS FlowCytomix Pro 2.2 Software in accordance with the manufacturer’s instructions. By the manufacturer’s instructions, the standard range was 27–20,000 for TNF-α, IL-6, and IL-1β.

Statistical tests were performed using GraphPad Prism 5 (Graph Pad Software, San Diego, CA, USA). Mann–Whitney U (nonparametric) test was used for comparison between the groups. The results were rendered as mean ± SD (standard deviation). If p was < 0.05, we considered the difference statistically significant.

RESULTS

Cytokine levels in smoking LSCC patients and smoking control groups

Concentrations of serum cytokines in smoking LSCC patients and smoking control individuals are presented in Table 1. No statistically significant difference was observed between these two groups of patients.

Table 1. Distribution of cytokine levels in smokers

| Cytokine | Cytokine level, mean ± SD (pg/mL) | p |
|----------|-----------------------------------|---|
|          | LSCC smokers | Control smokers |
| IL-6     | 39.40 ± 69.54 | 53.93 ± 91.18 | 0.7894 |
| IL-1β    | 191.3 ± 351.9 | 239.3 ± 408.4 | 0.6711 |
| TNF-α    | 143.2 ± 231.3 | 178.8 ± 312.7 | 0.7002 |

LSCC – laryngeal squamous cell carcinoma; SD – standard deviation

Figure 1. Comparison of interleukin (IL)-1β serum levels in smoking and non-smoking laryngeal squamous cell carcinoma (LSCC) patients

*p < 0.05

Figure 2. Comparison of interleukin TNF-α serum levels in smoking and non-smoking laryngeal squamous cell carcinoma (LSCC) patients

*p < 0.05

Cytokine levels in the Control Group according to smoking

Proinflammatory cytokines were not significantly different between controls who smoke and controls who do not smoke (Table 2).

DISCUSSION

As chronic infection and inflammation may lead to malignant cell transformation, a malignant tumor may also induce chronic inflammation. The intrinsic inflammatory pathway activated by genetic changes that cause neoplasia leads to an excessive production of inflammatory cytokines. This mechanism is observed in the activation of oncogenes such as MYC, RAS, RET, or inactivation of tumor suppressors. On the other hand, both extrinsic (alcohol)
IL-1β, IL-6, and TNF-α in asymptomatic smokers. Increased production of the pro-inflammatory cytokines (Table 2). In contrast to our results, Zeidel et al. [18] found no difference between smokers and non-smokers in control subjects, statistical analysis in healthy smoking individuals. Interestingly, according to our results, inflammation is not greater in cancer patients who smoke compared to inflammation in healthy smokers (Table 2, Figures 1 and 2). According to our results, cigarette smoking leads to a reduced proinflammatory response in LSCC patients. These observations may suggest that patients with LSCC are more susceptible to bacterial, viral, parasitic, and fungal infections, considering the role of IL-1β and TNF-α in host defensive mechanisms [6, 18].

Data regarding the effect of tobacco on systemic immune response is inconsistent. Suppression of inflammatory response is in accordance with Shielis et al. [20], who concluded that smoking leads to the suppression of systemic immune marker levels. In vitro studies also showed decreased production of IL-1β, IL-2, IFN-γ, and TNF-α by nicotine [21, 22]. Conversely, other authors showed increment of serum proinflammatory cytokine due to smoking [23, 24]. It is questionable whether inflammation is a sufficient factor to promote carcinogenesis. Chronic inflammation is observed in many other diseases apart from cancer. Chronic inflammation is present in Chronic obstructive pulmonary disease (COPD), while macrophage innate response, pro Th-1 and Th-17 response to bacteria is suppressed [25, 26]. Although the most prevalent, tobacco and inflammation, cannot be considered the only etiological factors in laryngeal carcinogenesis. Several studies have suggested an association between laryngeal cancer and heavy metal exposure, industrial heat, mustard gas, hair dye, nickel, wood dust, rubber, diesel and gasoline fumes, formaldehyde, asbestos, organic solvents, mineral oil, coal dust.

Studies which include subjects’ self-reported data on tobacco and alcohol consumption have certain limitations. This is primarily related to the fact that the measures of smoking exposure rely on self-reported data. Khariwala et al. [27] revealed that the carcinogen exposure in HNSCC patients does not correlate with self-reported tobacco use. The possible explanations for such inaccuracies could be that the patient is facing physicians’ expectations, fear, or guilt as he is treated for malignancy. Likewise, in healthy subjects, potential shame or embarrassment because of unhealthy habit can occur. The need for a more objective analysis of

Table 2. Distribution of cytokine levels in laryngeal squamous cell carcinoma patients and control subjects according to smoking

| Cytokine | Cytokine level mean ± SD (pg/mL) | p   | Cytokine level mean ± SD (pg/mL) | p   |
|----------|----------------------------------|-----|----------------------------------|-----|
|          | Smokers                          |     | Smokers                          |     |
|          | Non-smokers                      |     | Non-smokers                      |     |
| IL-6     | 39.4 ± 69.54                     | 0.4336 | 53.93 ± 91.18                   | 0.1895 |
| IL-1β    | 191.3 ± 351.9                    | 0.0450 | 239.3 ± 408.4                   | 0.5812 |
| TNF-α    | 143.2 ± 231.3                    | 0.0304 | 178.8 ± 312.7                   | 0.7314 |

LSCC – laryngeal squamous cell carcinoma; SD – standard deviation
tobacco exposure and carcinogen dose is also reflected in the fact that the number of cigarettes per day may not be the accurate measure of exposure. Variability in puffs per cigarette, depth of inhalation, type of cigarette or cigar can significantly influence the actual carcinogen exposure.

Like in our study, most of the published data refer to the serum cytokine levels. It is possible that cytokines serum levels may not represent the adequate tumor-host interaction since it may differ from the concentrations of immune mediators in tumor microcirculation.

CONCLUSION

The results of our study demonstrate the complex relationship between carcinogenesis, inflammation, environmental factors, and host factors. Our results show that smoking leads to significantly decreased (p < 0.05) serum levels of TNF-α and IL-1β in smoking LSCC patients compared to non-smoking patients. This data may suggest that these patients are more susceptible to bacterial, viral, parasitic, and fungal infections, reflecting an immunosuppressive effect of cigarette smoking in LSCC patients, while we did not perceive this effect of smoking in healthy subjects. Further investigations are needed to elucidate perplexed network of smoking, carcinogenesis, and host immunity.

ACKNOWLEDGEMENT

We sincerely thank Margareta Opsenica, whose help highly improved the manuscript.

This paper is a part of a doctoral thesis titled “Serum cytokine concentrations in patients with laryngeal squamous cell carcinoma.”

All authors conceived and planned the work that led to the paper and interpreted the evidence it presents. All authors participated in data collection and analysis, in writing of the paper, and they all approved the final version.

Conflict of interest: None declared.

REFERENCES

1. Irimie AI, Braicu C, Cojocneanu R, Magdo L, Onaciu A, Ciocan C, et al. Differential Effect of Smoking on Gene Expression in Head and Neck Cancer Patients. Int J Environ Res Public Health. 2018; 15(7).
2. Cui WY, Li MD. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor. J Neuroimmun Pharmacol. 2010; 5(4):479–88.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255):539–45.
4. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelis. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991; (262):3–11.
5. Kolodeck T, Shugrue C, Ashat M, Thrower EC. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol. 2014; 4:415.
6. Waters JP, Pober JS, Bradley JR. Tumor necrosis factor in infectious disease. J Pathol. 2013; 230(2):132–47.
7. Kubly J, Thompson R, Wilton JL, Robinson S, Hagemann T, Fathah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007; 67(2):585–92.
8. Popivanoza BK, Kitamura K, Wu Y, Kondo T, Kagaaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118(2):560–70.
9. Liu F, Al F, Tian L, Liu S, Zhao L, Wang X. Inflximbab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer. Onco Targets Ther. 2016; 9:5999–6008.
10. Bommert K, Bargou RC, Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006; 42(11):1574–80.
11. Millrud CR, Hylandner T, Kumljen Georen S, Kågedal Å, Wingqvist O, Cardell LO. Inverse immunological responses induced by allergic rhinitis and head and neck squamous cell carcinoma. PloS One. 2014; 9(1):e86796.
12. Ding X, Zhang J, Liu D, Xu W, Lu DY, Zhang LP, et al. Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. J Cancer. 2018; 9(5):792–6.
13. Evgor M, Evgor H, Osma U, Yilmaz MD, Erin N, Selcuk OT, et al. Analysis of serum cytokine levels in larynx squamous cell carcinoma and dysplasia patients. Iran J Immunol. 2014; 11(4):259–68.
14. Nikahlighi S, Ranbari N, Khorami E, Saki N. Association between serum levels of interleukin-6 and stage of laryngeal cancer. Iran J Otorhinolaryngol. 2015; 27(80):199–205.
15. Ozkureda YU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol. 2012; 167(3):382–90.
16. Chang PH, Pan YP, Fan CW, Tseng WK, Huang JS, Wu TH, et al. Pretreatment serum interleukin-1β, interleukin-6, and tumor necrosis factor-alpha levels predict the progression of colorectal cancer. Cancer Med. 2016; 5(3):426–33.
17. Bediaga NG, Marichalar-Mendia X, Rey-Barja N, Setien-Olarra A, Gonzalez-Garcia JA, de Pancorbo MM, et al. Polymorphisms in alcohol and tobacco metabolism genes in head and neck cancer in the Basque Country. J Oral Pathol Med. 2015; 44(10):769–75.
18. Zeidel A, Belin B, Yardeni I, Mayburd E, Smimov G, Bessler H. Immune response in asymptomatic smokers. Acta Anaesthesiol Scand. 2002; 46(8):595–64.
19. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003; 3(10):733–44.
20. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014; 106(11).
21. Ouyang Y, Virasch N, Hao P, Aubrey MT, Mukerjee N, Bierer BE, et al. Suppression of human IL-1β, IL-2, IFN-γ, and TNF-alpha production by cigarette smoke extracts. J Allergy Clin Immunol. 2000; 106(2):280–70.
22. Kim TH, Kim SJ, Lee SM. Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. Infect Dis. 2014; 209(10):1668–77.
23. Bermudez EA, Rifaï N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol. 2002; 89(9):1117–9.
24. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(10):1223–9.
25. Strzelak A, Rajaczkaz A, Adamiec A, Felezsko W. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review. Int J Environ Res Public Health. 2018; 15(S).
26. Le Rouzic O, Koné B, Klusa J, Marchetti P, Hennegreve F, Olivier C, et al. Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response. Respir Res. 2016; 17(1):94.
27. Khariwala SS, Carmella SG, Steprenian I, Bandyopadhyay D, Nelson HH, Yueh B, et al. Self-reported tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer. Laryngoscope. 2015; 125(8):1844–8.
Пушење и инфламација код планоцелуларног карцинома ларинкса

Јелена Сотировић1, Александар Перић1, Данило Војводић2, Ненад Балетић1, Миланко Милојевић1, Љубомир Павићевић1
1 Војномедицинска академија, Клиника за оториноларингологију, Београд, Србија;
2 Војномедицинска академија, Институт за медицинска истраживања, Београд, Србија

САЖЕТАК
Увод/Циљ Епидемиолошке студије јасно показују да је пушење цигарета један од најзначајнијих етиолошких фактора у патогенези ларингеалног планоцелуларног карцинома (LSCC). Једно од могућих объјашњења дејства дувана на карциногенезу је хронична инфламација. Међутим, подаци из литературе су често опречни у погледу утицаја пушења на системски имунски одговор.

Ова студија је имала за циљ одређивање концентрација проинфламаторних цитокина у серуму [фактор некрозе тумора (TNF)-α, интерлеукин (IL)-6, IL-1β] код болесника са LSCC и здравих испитаника у односу на пушење цигарета.

Методе У испитивању је учествовало 59 болесника са LSCC и 44 здрава испитаника. Од свих учесника у студији узети су подаци о пушењу цигарета, као и 5 ml периферне венске крви. Проточном цитометријом урађено је израчунавање концентрација цитокина у крви. Статистичком анализом поређене су концентрације цитокина испитаника у односу на пушење.

Резултати У групи испитаника са LSCC, серумске концентрације цитокина IL-1β и TNF-α биле су статистички значајно веће (p < 0,05) у групи непушача поредећи их са пушачима. Примењени статистички тестови нису показали постојање значајне разлике концентрација испитиваних цитокина у контролној групи у односу на то да ли испитаници пуше. Такође, концентрације испитиваних проинфламаторних цитокина у групи пушача са LSCC нису се разликовале у односу на здраве пушење.

Закључак Пушење има имуносупресивни ефекат на проинфламаторни одговор код болесника са LSCC. Групом пушача се разликовале у односу на здраве пушење.

Кључне речи: пушење; IL-6; IL-1β; TNF-α; планоцелуларни карцином ларинкса